Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has announced equity inducement grants for a newly hired employee. The compensation committee approved 15,000 restricted stock units (RSUs) and stock options for 30,000 shares on September 22, 2025.
The RSUs will fully vest after three years, while the stock options will vest one-third after the first year and 1/36th monthly thereafter. The stock options have a seven-year term and an exercise price at Fair Market Value. These grants were made under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione di sviluppo e produzione in contratto (CDMO), ha annunciato grant di incentivazione azionaria per un dipendente recentemente assunto. Il comitato per la retribuzione ha approvato 15.000 unità azioni vincolate (RSU) e opzioni su azioni per 30.000 azioni il 22 settembre 2025.
Le RSU matureranno completamente dopo tre anni, mentre le opzioni su azioni matureranno per un terzo dopo il primo anno e 1/36 mensilmente da allora. Le opzioni hanno un periodo di validità di sette anni e un prezzo di esercizio pari al Fair Market Value. Questi assegni sono stati concessi nell'ambito del Equity Inducement Plan di Lifecore, in conformità con la Nasdaq Listing Rule 5635(c)(4).
Lifecore Biomedical (NASDAQ: LFCR), una organización de desarrollo y fabricación por contrato (CDMO), ha anunciado asignaciones de incentivos de acciones para un empleado recién contratado. El comité de compensación aprobó 15,000 unidades de acciones restringidas (RSU) y opciones sobre acciones para 30,000 acciones el 22 de septiembre de 2025.
Las RSU se vencerán por completo después de tres años, mientras que las opciones se vencerán en un tercio tras el primer año y 1/36 mensualmente a partir de entonces. Las opciones tienen un vencimiento de siete años y un precio de ejercicio al Valor Justo de Mercado (Fair Market Value). Estas adjudicaciones se realizaron bajo el Equity Inducement Plan de Lifecore, de acuerdo con la Nasdaq Listing Rule 5635(c)(4).
Lifecore Biomedical(NASDAQ: LFCR), 계약 개발 및 제조 조직(CDMO), 신규 채용 직원에 대한 주식 보상 부여를 발표했습니다. 보상 위원회는 2025년 9월 22일 15,000주의 제한 주식 유닛(RSU)와 30,000주에 대한 주식 옵션을 승인했습니다.
RSU는 3년 후에 완전히 vesting되고, 주식 옵션은 1년 차에 1/3, 이후 매월 1/36씩 vesting됩니다. 주식 옵션은 7년 만료 기간이 있으며 행사 가격은 공정 시장 가치(FMV)입니다. 이 보상은 Nasdaq Listing Rule 5635(c)(4)에 따라 Lifecore의 Equity Inducement Plan에 따라 부여되었습니다.
Lifecore Biomedical (NASDAQ : LFCR), une organisation de développement et de fabrication sous contrat (CDMO), a annoncé des attributions d'incitations en actions pour un nouvel employé recruté. Le comité de rémunération a approuvé 15 000 unités d’actions restreintes (RSU) et des options sur actions pour 30 000 actions le 22 septembre 2025.
Les RSU se vesteront intégralement après trois ans, tandis que les options d’achat d’actions se vestent à hauteur d’un tiers après la première année et 1/36 mensuellement par la suite. Les options ont une durée de sept ans et un prix d’exercice au Fair Market Value. Ces attributions ont été réalisées dans le cadre du Equity Inducement Plan de Lifecore, conformément à la Nasdaq Listing Rule 5635(c)(4).
Lifecore Biomedical (NASDAQ: LFCR), eine Vertragsentwicklungs- und -herstellungsorganisation (CDMO), hat Aktien-Beteiligungszuteilungen für eine neu eingestellte Mitarbeiterin bzw. Mitarbeiter bekannt gegeben. Der Vergütungsausschuss hat am 22. September 2025 15.000 Restricted Stock Units (RSUs) und Aktienoptionen für 30.000 Aktien genehmigt.
Die RSUs verfallen nach drei Jahren vollständig, während die Aktienoptionen nach dem ersten Jahr ein Drittel vesten und danach monatlich 1/36 vesten. Die Optionen haben eine Laufzeit von sieben Jahren und einen Ausübungspreis zum Fair Market Value. Diese Zuteilungen wurden im Rahmen des Lifecore Equity Inducement Plan gemäß Nasdaq Listing Rule 5635(c)(4) vorgenommen.
Lifecore Biomedical (NASDAQ: LFCR)، منظمة تعاقدية للتطوير والتصنيع (CDMO)، أعلنت عن منح حوافز أسهم لموظف تم توظيفه حديثاً. وافقت لجنة التعويض على 15,000 وحدة أسهم مقيدة (RSUs) و خيارات أسهم لـ 30,000 سهم في 22 سبتمبر 2025.
ستكتسب RSUs كاملًا بعد ثلاث سنوات، بينما ستكتسب خيارات الأسهم تدريجيًا بمقدار الثلث بعد السنة الأولى وتدريجيًا شهرياً بمعدل 1/36 بعد ذلك. لدى خيارات الأسهم فترة سبع سنوات، وسعر ممارسة يعادل القيمة السوقية العادلة. جرى منح هذه الحوافز بموجب خطة Equity Inducement Plan لشركة Lifecore وفقاً لقواعد Nasdaq 5635(c)(4).
Lifecore Biomedical（纳斯达克: LFCR），一家合同开发与制造组织（CDMO），宣布为新聘员工授予股权激励。薪酬委员会已于2025年9月22日批准 15,000份受限股票单位（RSUs） 和 30,000股股票期权。
RSU 将在三年后完全归属，而股票期权将在人年第一年后归属三分之一，之后按每月1/36 的速率逐步归属。这些期权的有效期为七年，行使价格等于公允市场价值（FMV）。这些授予是根据 Lifecore 的 Equity Inducement Plan，并符合纳斯达克上市规则 5635(c)(4) 发放的。
- None.
- None.
CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired employee of Lifecore. The RSU award and stock options were granted on September 22, 2025, pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore.
The RSU award and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.
The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
What equity grants did Lifecore Biomedical (LFCR) announce on September 23, 2025?
What are the vesting terms for Lifecore's (LFCR) new equity grants?
What is the exercise price for Lifecore's (LFCR) inducement stock options?
Why did Lifecore Biomedical (LFCR) issue these equity grants?
